BioPharm Weekly News Roundup—Week of Oct. 27, 2025

Welcome to the BioPharm International® weekly news roundup for the week of Oct. 27, 2025. In this video feature, the editors highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

CPHI Frankfurt 2025 unites the global pharmaceutical community, emphasizing partnership and integrating the end-to-end supply chain.

AI-driven organ-on-chip platforms are revolutionizing bio/pharma drug R&D, cutting costs, reducing failure rates, and enabling personalized medicine.

AI adoption in biopharma manufacturing is hindered by poor data quality, despite regulators providing necessary GxP guidelines.

The 2025 CPHI Pharma Awards recognized continuous manufacturing, drug delivery, peptide synthesis, sustainability, and workforce inclusion advances in bio/pharma.

European biopharma requires accelerated innovation and regulatory adaptation to overcome structural challenges and boost global competitiveness.

AI in biomanufacturing requires regulatory risk assessment based on patient impact, necessitating cloud computing and ALCOA data integrity.

Enzymatic platforms like ECO Synthesis offer novel siRNA manufacturing pathways to boost RNA supply chain scalability and sustainability.

AI and digital transformation improve biomanufacturing efficiency via digital twins, requiring companies to address the significant skills gap through staff upskilling.

Novartis's $12 billion acquisition of Avidity Biosciences accelerates next-gen RNA therapeutics using the AOC platform for targeted neuromuscular disease treatment.

Enzyme engineering leverages molecular modeling and AI to efficiently improve industrial biocatalysis for sustainability.

Organ-on-chip technology, combined with AI, revolutionizes preclinical testing by enabling personalized medicine and multi-organ modeling.

Personalized medicine requires miniaturized, single-platform nanoparticle quality control as AI features offer staff guidance through complex method development compliance.

Nanoparticle quality control for RNA therapeutics is streamlined using existing systems, providing robust analytical readout crucial for personalized medicine.

Global vaccine manufacturing requires regulatory harmonization and strategic capacity building in LMIC regions to ensure product safety and efficacy.

Biomanufacturing achieves speed and sustainability through digital integration, AI, mobile designs, and strategic CDMO partnerships.

AI adoption in biologics is fundamentally stalled by poor data quality, despite regulators establishing GXP guidelines.